{"product_id":"biolegend-108108","title":"Biolegend, 108108, PE anti-mouse Ly-6A\/E (Sca-1) Antibody, 200μg","description":"\u003cp\u003eLy-6A\/E, also known as Sca-1, is an 18 kD member of the Ly-6 multigene family. Ly6A\/E is a glycosylphosphatidylinositol (GPI)-linked protein expressed on hematopoietic stem cells. In mice expressing the Ly-6.2 haplotype (e.g., AKR, C57BL, C57BR, DBA\/2, SJL, SWR, and 129), Ly-6A\/E is also expressed on peripheral B lymphocytes and thymic and peripheral T lymphocytes. Strains expressing the Ly-6.1 haplotype (e.g., BALB\/c, CBA, C3H\/He, DBA\/1, and NZB) have low Ly-6A\/E expression on resting peripheral lymphocytes. The expression of Ly-6A\/E on lymphocytes is upregulated upon activation from both Ly6.1 and Ly6.2 haplotype mice. Ly-6A\/E is thought to be involved in the regulation of both T and B cell responses.\u003cbr\u003e\n200μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: IL-2-dependent mouse T-cell line (CTL-L)\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting1,2, immunoprecipitation1, in vitro lymphocyte activation3-6, induction of redirected lysis7, induction of T cell inhibitory signalling8, immunofluorescence9, and immunohistochemical staining of acetone-fixed frozen sections13 and Bouin-fixed, paraffin-embedded samples9. The two Sca-1 recognizing clones D7 and E13-161.7 have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7.14\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ortega G, et al. 1986. J. Immunol. 137:3240. (WB, IP) Palfree RGE, et al. 1986. Immunogenetics 23:197. (WB) Codias EK, et al. 1990. J. Immunol. 144:2197. Malek TR, et al. 1986. J. Exp. Med. 164:709. Codias EK, et al. 1990. J. Immunol. 145:1407. Ivanov V, et al. 1994. J. Immunol. 153:2394. Karlhofer FM, et al. 1991. J. Immunol. 146:3662. Fleming T, et al. 1994. J. Immunol. 153:1955. van Bragt MPA, et al. 2005. Biol. Reprod. 73:634. (IF, IHC) Umland O, et al. 2007. J. Immunol. 178:4147. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 45:149. (FC) PubMed Pronk CJ, et al. 2011. J. Exp Med. PubMed English A, et al. 2000. J. Immunol. 165:3763. (IHC) Bamezai A and Rock KL. 1995. Proc. Natl. Acad. Sci. USA 92:4294. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed\u003cbr\u003e\nProduct Citations: Perveen S, et al. 2012. PLoS One. 7:e51945. PubMed Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed Enquist I, et al. 2009. Stem Cells. 27:744. PubMed Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed Han X, et al. 2023. J Clin Invest. 133:. PubMed Guan H, et al. 2023. Int J Mol Sci. 24:. PubMed Sang H, et al. 2023. Adv Clin Exp Med. 32:551. PubMed Xiao Y, et al. 2023. EMBO J. 42:e111762. PubMed Zhou Y, et al. 2023. NPJ Regen Med. 8:23. PubMed Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed Li Y, et al. 2022. J Exp Clin Cancer Res. 41:128. PubMed Kobayashi S, et al. 2022. Inflamm Regen. 42:49. PubMed Guo J, et al. 2023. Cell Rep Med. 4:100881. PubMed Wang L, et al. 2020. Cell Metab. 32:860. PubMed Yang M, et al. 2020. Cell Prolif. 53:e12784. PubMed Sieveking D, et al. 2010. J Exp Med. 207:345. PubMed Wu R, et al. 2019. J Cell Mol Med. 24:1684. PubMed Li J, et al. 2022. Int J Biol Sci. 18:2091. PubMed Cui Z, et al. 2022. Bone Res. 10:58. PubMed Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed Li J, et al. 2019. JCI Insight. 5. PubMed Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed Flommersfeld S, et al. 2021. Immunity. :. PubMed Phan QM, et al. 2020. Elife. 9:00. PubMed Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed Zhao J, et al. 2018. Stem Cell Reports. 10:180. PubMed Marinescu CI, et al. 2021. Stem Cell Res Ther. 12:319. PubMed Hu Y, et al. 2021. Bioact Mater. 2905:6. PubMed Wang X, et al. 2018. Cell Death Dis. 9:578. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Oka Y, et al. 2020. Sci Adv. 6:. PubMed Chen Z, et al. 2019. J Exp Med. 216:152. PubMed Gao Y, et al. 2020. Immunity. 52(6):1007-1021.e8. PubMed N. H, et al. 2017. Journal of Vascular Research. 10.1159\/000464287. PubMed Sun J et al. 2018. Cell stem cell. 23(3):355-369 . PubMed Li CJ, et al. 2018. J Clin Invest. 128:5251. PubMed Hou J, et al. 2017. Mol Med Rep. 16:1502. PubMed Nowlan B, et al. 2019. Haematologica. 105:71. PubMed Xu X, et al. 2022. EMBO Rep. 23:e53509. PubMed Zelco A, et al. 2020. Front Cell Neurosci. 0.75625. PubMed Schwörer S, et al. 2016. Nature. 540:428-432. PubMed Rüder C, et al. 2014. PLoS One. 9:104644. PubMed Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed Kwiecien K, et al. 2020. Sci Rep. 10:13702. PubMed Bruno C, et al. 2020. Brain Commun. 2:fcaa133. PubMed Miura Y et al. 2018. eLife. 7 pii: e36572. PubMed Ge Q, et al. 2018. Mol Med Rep. 17:1667. PubMed Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed Kopinke D et al. 2017. Cell. 170(2):340-351 . PubMed Li ZG, et al. 2020. Chin Med J (Engl). 1943:133. PubMed Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed Young K, et al. 2021. Cell Stem Cell. . PubMed\u003cbr\u003e\nRRID: AB_313344 (BioLegend Cat. No. 108107) AB_313345 (BioLegend Cat. No. 108108)\u003cbr\u003e\nStructure: Ly-6 multigene family, 18 kD\u003cbr\u003e\nDistribution: Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells\u003cbr\u003e\nFunction: Regulates B and T cell responses\u003cbr\u003e\nCell Type: B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells\u003cbr\u003e\nBiology Area: Immunology, Stem Cells\u003cbr\u003e\nAntigen References: 1. Rock KL, et al. 1989. Immunol. Rev. 111:195. 2. Morrison SJ, et al. 1994. Immunity 1:661. 3. Spangrude GJ, et al. 1988. J. Immunol. 141:3697. 4. Malek T, et al. 1986. J. Exp. Med. 164:709.\u003cbr\u003e\nGene ID: 110454\u003cbr\u003e\nUniProt: View information about Ly-6A\/E on UniProt.org\u003cbr\u003e\nClone: D7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Sca-1\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863003386025,"sku":"108108","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-108108","provider":"Iright","version":"1.0","type":"link"}